| 21 Dec 2007 | Aeras and Crucell Announce Start of a Tuberculosis Vaccine Clinical Trial in the United States. Aeras commits a further USD 5 million to the development of the tuberculosis vaccine |
| 18 Dec 2007 | DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Medarex Inc. |
| 17 Dec 2007 | Crucell Announces Research License Agreement with ProFibrix on STAR® Technology |
| 30 Nov 2007 | Crucell Presents Indian Phase I Rabies Antibody Cocktail Study, Positive Results Enable Prompt Progression Towards Phase II Studies |
| 20 Nov 2007 | Crucell Announces PER.C6® Licensing Agreement with Acambis |
| 16 Nov 2007 | DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Daiichi Sankyo Ltd. |
| 13 Nov 2007 | Crucell Announces Third Quarter 2007 Results |
| 13 Nov 2007 | Crucell's Rabies Antibody Cocktail Granted Fast Track Status |
| 12 Nov 2007 | Crucell Sells Stake in Pevion Biotech |
| 12 Nov 2007 | Crucell Announces Marketing and Distribution Deal with Sanquin |
| 06 Nov 2007 | Crucell to Release Q3 2007 Earnings on Tuesday, November 13, 2007 |
| 02 Nov 2007 | DSM Biologics and Crucell Announce PER.C6® Technology Licensing Agreement with Recepta Biopharma S.A. |
| 15 Oct 2007 | Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection |
| 03 Oct 2007 | Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect |
| 27 Sep 2007 | Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus. The antibody provides immediate protection and neutralizes the broadest range of H5N1 strains. |
| 25 Sep 2007 | Impact of discontinuation of Merck HIV study on Crucell's prospects |
| 14 Sep 2007 | Crucell to present pre-clinical results for H5N1 Virus treatment |
| 10 Sep 2007 | Crucell Appoints Mr. Cees de Jong as Chief Operating Officer |
| 10 Sep 2007 | Crucell grants Merck & Co., Inc. access to vaccine technology |
| 06 Sep 2007 | Crucell announces new STAR® technology research license in agreement with Invitrogen Corporation |
| 14 Aug 2007 | Crucell Announces Second Quarter 2007 Results |
| 31 Jul 2007 | Crucell to Release Q2 2007 Earnings on Tuesday, August 14, 2007 |
| 30 Jul 2007 | Crucell Announces PER.C6® and AdVac® Technology License Agreement with Wyeth Pharmaceuticals |
| 25 Jul 2007 | DSM Biologics and Crucell Announce PER.C6® Licensing Deal With LFB Biotechnologies. |
| 18 Jul 2007 | Crucell announces Vaccine and Protein Business Unit Structure and Management Appointments |
| 10 Jul 2007 | DSM Biologics and Crucell Announce PER.C6® Licensing Deal With Masterclone |
| 06 Jun 2007 | Crucell CFO to present at two June Investor Conferences |
| 05 Jun 2007 | DSM Biologics and Crucell Announce PER.C6® Licensing Deal With Sartorius Biotech GmbH |
| 01 Jun 2007 | Crucell announces resignations of Supervisory Board members, Dr. Jürg Witmer and Dr. Claude Thomann |
| 30 May 2007 | Crucell announces live webcast of Annual General Meeting of Shareholders |
| 11 May 2007 | Crucell, AERAS and SATVI Announce Start of Tuberculosis Vaccine Clinical Trial in South Africa six months after launching initial trial in the United States |
| 09 May 2007 | Crucell Announces First Quarter 2007 Results |
| 08 May 2007 | Crucell CFO to present at Rodman & Renshaw Conference in Monaco |
| 27 Apr 2007 | Crucell Announces PER.C6® Licensing Agreement |
| 26 Apr 2007 | Crucell to Release Q1 2007 Earnings on Wednesday, May 9, 2007 |
| 26 Apr 2007 | Crucell celebrates 10th anniversary of Inflexal® V |
| 05 Apr 2007 | Crucell broadens pandemic preparedness with grant awarded to develop H5N1 Influenza vaccine |
| 04 Apr 2007 | Crucell Announces Start of Rabies Phase I Antibody Cocktail Clinical Study in India four months after launching initial US Trial |
| 03 Apr 2007 | Crucell secures important patent covering influenza vaccine production |
| 03 Apr 2007 | Crucell announces European protein distribution deal with Talecris Biotherapeutics |
| 26 Mar 2007 | DSM Biologics and Crucell Announce PER.C6® Licensing Deal with Taiwanese Development Center for Biotechnology |
| 23 Mar 2007 | Crucell Announces Large Scale Quinvaxem(TM) Vaccinations in Ethiopia |
| 22 Mar 2007 | Crucell announces influenza alliance with ADImmune Corporation |
| 15 Mar 2007 | Crucell Announces PER.C6® Licensing Agreement with Pfizer Animal Health |
| 07 Mar 2007 | Aeras commits further USD$5 million to existing TB research agreement with Crucell |
| 14 Feb 2007 | DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6® technology platform. |
| 13 Feb 2007 | Crucell announces fourth quarter and annual results 2006 |
| 08 Feb 2007 | Crucell and DSM intensify collaboration and development of PER.C6® human cell line |
| 31 Jan 2007 | Crucell to Release 2006 Earnings on Tuesday, February 13, 2007 |
| 31 Jan 2007 | Crucell announces STAR(TM) Research License Agreement |
| 26 Jan 2007 | Crucell's PER.C6®-based West Nile Vaccine Demonstrates Excellent Safety and Tolerability |
| 24 Jan 2007 | Crucell awarded EU grant to develop malaria vaccine |
| 16 Jan 2007 | Crucell announces STAR(TM) Research License Agreement with Novo Nordisk A/S |
| 11 Jan 2007 | Crucell and DSM Biologics announce PER.C6® license agreement with AbGenomics Corporation |
| 05 Jan 2007 | DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Biotecnol SA for Antibody Production |
About Us
